[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infant-newborn\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infant-newborn":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,47,99,148,178,211,237,258,289,321,364,405,431,469,517,544],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":46},"100058940","follow-up-visit-of-high-risk-infants-100058940",false,"NCT00009633","Follow-up Visit of High Risk Infants","FU","* Infants inborn at NRN centers\n* \\\u003C27 weeks gestational age\n* Infants enrolled in one or more additional NICHD NRN Follow-up studies. For infants that do not meet the inclusion criteria above, inclusion and exclusion criteria are determined by the criteria for the additional trial(s). In these cases, infants that are larger than 1,000 grams and\u002For older than 27 weeks may be included in the FU Study.\n\nNote: These inclusion criteria were changed as of 1\u002F1\u002F2008. Prior to this date, infants with birth weights between 401 and 1500 grams who were admitted to NRN NICUs within 14 days of birth were included in the database.","ALL","18 Months","26 Months",{"count":20,"type":21},68000,"ESTIMATED","OBSERVATIONAL","The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may affect infant neurodevelopment.",[25,26,27,28],"Infant, Newborn","Infant, Low Birth Weight","Infant, Small for Gestational Age","Infant, Premature",[30,31,32,33,34],"NICHD Neonatal Research Network","Extremely Low Birth Weight (ELBW)","Prematurity","Neurodevelopmental Outcome","Follow up studies","RECRUITING","2026-06-29",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":39},"1993-04-01",{"date":43,"type":21},"2030-03-31",{"name":30,"class":45},"NETWORK",31,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":61,"conditions":62,"keywords":70,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100601587","phase-1-fentanyl-intranasal-for-retinopathy-of-prematurity-screening-in-preterm-infants-100601587","NCT07112430","Fentanyl Intranasal for Retinopathy of Prematurity Screening in Preterm Infants","Intranasal Fentanyl to Reduce Pain Intensity Associated With Retinopathy of Prematurity Screening in Preterm Infants: A Randomized Control Trial","FIREFLY","Inclusion Criteria\n\n* Preterm infants born ≤31 weeks gestational age and\u002For with birth weight \\\u003C1250 g\n* Scheduled to undergo routine retinopathy of prematurity (ROP) screening as part of standard NICU care\n* Clinically stable at the time of screening, defined as not requiring acute resuscitative support (no bag-mask ventilation, intubation, or chest compressions within the preceding 24 hours) and maintaining stable cardiorespiratory parameters on baseline respiratory support\n* Written informed consent obtained from a parent or legally authorized representative\n\nExclusion Criteria\n\n* Congenital anomalies or conditions affecting the nasal passages that would interfere with intranasal drug administration\n* Receipt of systemic opioids, benzodiazepines, barbiturates, or other sedative\u002Fanalgesic medications within 24 hours prior to the ROP examination\n* Known hypersensitivity or prior adverse reaction to fentanyl",{"count":56,"type":21},58,"INTERVENTIONAL",[59,60],"PHASE1","PHASE2","The goal of this clinical trial is to learn whether intranasal fentanyl (a pain medicine given as a nasal spray) can reduce pain and is safe to use during routine eye examinations for retinopathy of prematurity (ROP) in preterm infants. ROP is an eye condition that can affect babies born too early and requires regular eye examinations. The main questions this study aims to answer are: Does intranasal fentanyl lower pain during ROP screening? Is intranasal fentanyl safe for preterm infants? Researchers will compare intranasal fentanyl with a placebo (a saltwater spray that contains no medicine) to determine whether the medicine lowers pain during ROP screening.\n\nParticipants will receive either intranasal fentanyl or placebo before their routine ROP eye examination, in addition to the standard comfort measures normally used during the procedure. Researchers will measure participants' pain and monitor their heart rate, oxygen levels, and any side effects during and after the examination.",[63,64,65,28,66,25,67,68,69],"Neonatal Pain","Retinopathy of Prematurity (ROP)","Pain Management","Fentanyl","Neonatal Intensive Care Units","Analgesia","Intranasal Drug Administration",[71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86],"intranasal fentanyl","fentanyl","neonatal analgesia","procedural pain","ROP screening","Retinopathy of Prematurity","Preterm infants","Premature infants","infant pain","Non-invasive analgesia","Opioid analgesia","Intranasal drug delivery","Neonatal intensive care","NICU","Pain management in neonates","Infant procedural sedation","NOT_YET_RECRUITING","2026-06-26",{"date":90,"type":39},"2026-06-30",{"date":92,"type":21},"2026-09-09",{"date":94,"type":21},"2028-06-01",{"name":96,"class":97},"Marsha Campbell-Yeo","OTHER",1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":16,"minAge":4,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":57,"phases":111,"briefSummary":112,"conditions":113,"keywords":118,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":147},"100607502","phase-2-the-bloom-infant-probiotic-bip-study-100607502","NCT07189390","The Bloom Infant Probiotic (BIP) Study","A Randomised Controlled Trial to Assess if a Probiotic Intervention Leads to Enhanced Immune Responses to Vaccination in Antibiotic-treated Infants (Bloom Infant Probiotic (BIP) Study)","BIP","Inclusion Criteria:\n\n1. Infants administered antibiotics in the first 28 days of life. Infants must have documented direct antibiotic exposure - defined as having received at least 36 hours of antibiotic treatment in the neonatal period (the first 28 days after birth).\n2. Gestational age ≥ 35 weeks.\n3. Birth weight ≥ 2500g.\n4. Mother aged at least 18 years and able and willing to provide written informed consent for themselves and their infant.\n5. Parent\u002Fguardian agrees to not give any other probiotics to their infant prior to vaccination at 6 weeks, including any formula that contains probiotics.\n6. Infant planning to receive all nationally approved vaccines during next 6 months.\n\nExclusion Criteria:\n\n1. Significant medical condition in either the mother or infant that, in the opinion of a medical investigator, may interfere with the study.\n2. Infant had confirmed sepsis or other serious infection in the neonatal period.\n3. Infants with known congenital diseases or who are immunocompromised or considered medically at risk (MAR).\n4. Infant participating in another interventional trial during the trial period.",true,"28 Days",{"count":110,"type":21},360,[60],"The goal of this clinical trial is to investigate whether administering a probiotic (Infloran®) to infants who received antibiotics in the first 28 days of life can restore or enhance their immune response to routine vaccines.\n\nAntibiotic use in the first weeks of life can lower the levels of beneficial gut bacteria, such as bifidobacteria, which play a key role in immune function. As a result, infants treated with antibiotics may produce fewer antibodies after routine vaccinations, leaving them less protected against infections.\n\nThe main questions this study aims to answer are:\n\n* Does treatment with the probiotic Infloran® improve the geometric mean concentrations (GMCs) of anticapsular antibodies against at least 11 serotypes included in the pneumococcal conjugate vaccine (PCV20) in serum samples collected at 6 months of age compared with placebo in infants treated with antibiotics in the neonatal period?\n* Does treatment with the probiotic Infloran® improve the GMCs for the pneumococcal conjugate vaccine (PCV20) at 12 months of age compared with placebo in infants treated with antibiotics in the neonatal period?\n* Does treatment with the probiotic Infloran® improve the GMCs of other routine childhood vaccines at 6 and 12 months of age compared with placebo in infants treated with antibiotics in the neonatal period?\n* Does treatment with the probiotic Infloran® increase the proportion of infants achieving seroprotective antibody levels for pneumococcal antigens compared to placebo in infants treated with antibiotics in the neonatal period?\n* What are the differences in antigen specific T cell responses, flow cytometry, blood transcriptomics, and gut microbiota composition in the probiotic (Infloran®) vs placebo groups in infants treated with antibiotics in the neonatal period?\n\nResearchers will compare infants who receive Infloran® (a probiotic containing Bifidobacterium bifidum and Lactobacillus acidphilus) with those who receive a placebo (which contains the same excipients as Infloran® but does not contain any bacterial strains).\n\nParticipants will:\n\n* Be randomly assigned to receive either a 14-day course of probiotic Infloran® or a placebo.\n* Provide blood samples (3-5 mL) at 6 weeks, 6.5 weeks (optional blood-draw for exploratory endpoint), 6 months and 12 months of age.\n* Provide stool samples at four timepoints: prior to starting the intervention (probiotic\u002Fplacebo), on day 7, on day 14 after completion of the study supplement, and prior to their first vaccination at 6 weeks of age.\n* Receive routine vaccinations at 6 weeks, 4 months and 6 months in line with the National Immunisation Program\n* Complete surveys to collect information regarding probiotic\u002Fplacebo administration and vaccination related side effects\n\nThis study aims to recruit 360 infants to assess whether this probiotic treatment following antibiotic exposure improves the immunogenicity of vaccinations. The information from this study will improve our understanding of how probiotic intervention can support optimal immune responses to vaccination in early life. The findings could potentially influence public health strategies, offering a new way to support optimal vaccine responses in antibiotic-treated infants.",[25,114,115,116,117],"Immunity","Immunisation","Antibiotic Treatment","Microbiome Dysbiosis",[119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137],"infant","newborn","neonate","antibiotic","microbiome","microbiota","gut","probiotics","bifidobacteria","bifidobacterium","infloran","immunisation","immunity","immune system","vaccine","vaccination","immunization","randomised controlled trial","randomized controlled trial","2026-05-24",{"date":140,"type":39},"2026-05-28",{"date":142,"type":39},"2026-05-25",{"date":144,"type":21},"2029-10",{"name":146,"class":97},"South Australian Health and Medical Research Institute",2,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":156,"maxAge":108,"enrollmentInfo":157,"targetDuration":4,"studyType":57,"phases":159,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":4},"100636629","ultrasound-guided-long-vs-short-peripheral-iv-catheters-in-neonates-with-congenital-syphilis-receiving-antibiotics-100636629","NCT07568171","Ultrasound-Guided Long vs Short Peripheral IV Catheters in Neonates With Congenital Syphilis Receiving Antibiotics","Ultrasound-Guided Long Peripheral Intravenous Catheters Versus Conventional Short Peripheral Catheters for Reducing Post-Insertion Failure in Neonates With Congenital Syphilis Receiving Antibiotic Therapy: A Randomized Clinical Trial","ULTRA-ACCESS","Inclusion Criteria:\n\n* Newborns admitted to the Neonatal Intermediate Care Unit;\n* Diagnosis of congenital syphilis;\n* Indication for intravenous penicillin therapy for an estimated duration of 10 days;\n* Enrollment on the first day of treatment.\n\nExclusion Criteria:\n\n* Newborns who have received any type of peripheral venous catheter prior to study enrollment;\n* Clinical instability at the time of vascular access indication and\u002For requirement for admission to a Neonatal Intensive Care Unit;\n* Requirement for concomitant administration of another antimicrobial agent in addition to crystalline penicillin;\n* Need for catheter insertion outside the operating hours of the Vascular Access Program (7:00 AM to 7:00 PM, Monday to Friday).","1 Day",{"count":158,"type":21},104,[160],"NA","Congenital syphilis in newborns requires intravenous antibiotic therapy, making reliable peripheral venous access essential. However, high rates of catheter failure and repeated punctures remain a significant clinical challenge. This randomized, controlled, parallel clinical trial aims to compare ultrasound-guided long peripheral intravenous catheters inserted by a specialized vascular access team with conventional short peripheral catheters inserted by neonatal nurses. A total of 104 newborns with congenital syphilis receiving intravenous penicillin will be randomly assigned to either group. The primary outcome is functional dwell time. Secondary outcomes include catheter failure, number of insertion attempts, first-attempt success, complications, and total number of devices required. The study hypothesizes that ultrasound-guided long peripheral catheters will improve vascular access outcomes, reduce complications, and minimize the need for repeated punctures.",[25,163,164,165,166,167,168],"Syphilis, Congenital","Catheterization, Peripheral","Ultrasonography","Advanced Practice Nursing","Patient Safety","Neonatal Nursing","2026-05-06",{"date":171,"type":39},"2026-05-11",{"date":173,"type":21},"2026-05",{"date":175,"type":21},"2028-12",{"name":177,"class":97},"Hospital de Clinicas de Porto Alegre",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":185,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":57,"phases":189,"briefSummary":190,"conditions":191,"keywords":196,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":210},"100574304","a-stepped-wedge-cluster-randomised-trial-of-video-versus-direct-laryngoscopy-for-intubation-of-newborn-infants-100574304","NCT06757543","A Stepped Wedge Cluster Randomised Trial Of Video Versus Direct Laryngoscopy For Intubation Of Newborn Infants","NEU-VODE","Inclusion Criteria:\n\n* Infants of any gestational age in whom endotracheal intubation is attempted can be included in this study once there is parental consent to the use their infant's data.\n\nExclusion Criteria:\n\n* Infants will be excluded if parents do not consent for their infants' data to be used.","0 Minutes","1 Month",{"count":188,"type":21},840,[160],"Many newborn babies have difficulty breathing. When babies need a lot of help, a doctor will intubate them - i.e. put a tube into their windpipe (trachea) - so that they can be given support with a breathing machine. Intubation is a difficult procedure, during which many babies have falls in their blood oxygen levels and heart rate. When doctors intubate babies, they use a device called a laryngoscope to identify the entrance to the windpipe. A standard laryngoscope has a light at its tip. When doctors use this device, they insert it into the baby's mouth and then look directly into the mouth to find the entrance (direct laryngoscopy). Less than half of first attempts to insert a tube are successful using this device. More recently, video laryngoscopes have been developed. These devices also have a camera at the tip and display a magnified view of the entrance to the windpipe on a screen. A study at one hospital showed that the doctors there inserted the tube at the first attempt more often when they used a video laryngoscope instead of a standard laryngoscope. This study was not large enough to see whether fewer babies had low oxygen levels or heart rate during the procedure.\n\nThe goal of this clinical trial is to see whether more newborn babies are intubated at the first attempt without falls in their blood oxygen levels or heart rate when the doctors use video laryngoscopy compared to direct laryngoscopy.\n\nHospitals where doctors routinely intubate babies by looking directly into the mouth will take part in the NEU-VODE study. From the start of the study, the doctors at each hospital will continue with their usual approach to intubation and collect information about intubation attempts. As the study progresses, the doctors at each participating hospital will switch one--by-one to routinely attempting intubation with a video laryngoscope. The date on which they switch will be determined by chance. By the end of the study, each hospital will have had a study period where babies were routinely intubated using direct laryngoscopy and video laryngoscopy.\n\nAt the end of the study, the information collected from all the babies intubated during the study will be compared to see if more babies were successfully intubated at the first attempt without falls in their blood oxygen levels or heart rate in the video laryngoscopy group.",[192,193,25,194,195],"Intubation","Intubation Complications","Infant Respiratory Distress Syndrome","Video Laryngoscopy",[197,198,199,200],"infant, newborn","video laryngoscopy","intubation","stepped wedge cluster randomised trial","2026-04-28",{"date":203,"type":39},"2026-05-04",{"date":205,"type":39},"2025-01-13",{"date":207,"type":21},"2026-08-31",{"name":209,"class":97},"University College Dublin",17,{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":107,"sex":16,"minAge":185,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":221,"conditions":222,"keywords":226,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":233,"leadSponsor":235,"locationsCount":4},"100608409","maternal-smoking-exposure-and-newborn-outcomes-a-study-using-cord-blood-cotinine-100608409","NCT07201181","Maternal Smoking Exposure and Newborn Outcomes: A Study Using Cord Blood Cotinine","Association of Prenatal Tobacco Exposure, Classified by Cord Blood Cotinine (Active, Passive, None), With Neonatal Metabolic and Physiologic Indices: A Single-Center Prospective Cohort Study","Inclusion Criteria:\n\n* Liveborn neonate delivered at the study hospital, aged 0-72 hours at assessment.\n* Routine umbilical cord blood gas available at birth (pH, base excess, lactate).\n* Cord blood cotinine available or obtainable at delivery for exposure classification.\n* Singleton live birth at ≥35 weeks of gestation.\n* Availability of routine umbilical cord blood gas parameters at birth, including at minimum pH, base excess, and lactate, with FCOHb recorded where available.\n* Availability of routine first postnatal day clinical and laboratory data according to unit practice.\n* Parent\u002Fguardian provides informed consent for use of neonatal data obtained from routine care.\n* Standard newborn assessments obtainable within 72 hours (e.g., birthweight, \\~6-hour vitals\u002FBP, TSH at 24-48 h, hearing screen ≤72 h per unit practice).\n\nExclusion Criteria:\n\n* Emergent clinical scenarios where any research step could delay urgent care.\n* Major congenital anomaly, known chromosomal\u002Fgenetic disorder, or major metabolic disease likely to affect neonatal adaptation or study outcomes.\n* Severe perinatal condition preventing acquisition of core study data or making outcome interpretation unreliable, including major birth trauma or prolonged intensive care requirement.\n* Missing cord blood cotinine measurement or missing core primary outcome data.\n* Multiple gestation.\n* Prior enrollment of the same neonate (no re-enrollment).","72 Hours",{"count":220,"type":21},126,"Prenatal exposure to tobacco smoke, whether from active maternal smoking or secondhand exposure, has been associated with adverse neonatal adaptation, metabolic stress, and impaired fetal oxygenation. This single-center prospective observational cohort study will quantify prenatal tobacco exposure using cord blood cotinine measured at delivery and examine its association with early neonatal biochemical, metabolic, and physiologic outcomes.\n\nParticipants will consist of mother-newborn dyads recruited consecutively at a tertiary academic hospital. After informed consent, cord blood obtained at delivery will be used for cotinine measurement. Based on pre-specified cotinine thresholds and maternal smoking history, newborns will be classified into three exposure groups: active exposure, passive exposure, or no exposure. No experimental intervention will be administered, and neonatal assessments will be based on routine perinatal and postnatal care.\n\nNeonatal data collected will include umbilical cord blood gas parameters (pH, pCO2, pO2, base excess, bicarbonate, and lactate), fetal carboxyhemoglobin (FCOHb), birthweight and anthropometric measurements, Apgar scores, oxygen saturation, heart rate, blood pressure, and routine laboratory indices obtained during the first postnatal day. These laboratory measures may include complete blood count parameters, inflammatory and hematologic ratios such as NLR and PLR, metabolic markers including albumin and lactate-to-albumin ratio, lipid parameters such as HDL and LDL, thyroid-stimulating hormone from the standard newborn screening program, and hearing screening results. Early follow-up data, including postnatal weight loss and bilirubin measurements at routine visits, will also be recorded where available. Maternal and perinatal covariates, including maternal age, parity, gestational age, delivery mode, intrapartum factors, smoking history, and relevant maternal comorbidities, will be collected to support adjusted analyses.\n\nThe primary objective is to determine whether higher cord blood cotinine-defined exposure is associated with greater metabolic stress and impaired fetal oxygenation at birth, particularly as reflected by cord lactate, related blood gas parameters, and FCOHb. Secondary objectives include evaluating associations with early neonatal hematologic, metabolic, endocrine, and clinical indices, including birthweight, blood pressure, bilirubin levels, thyroid screening results, and hearing screening outcomes.\n\nThe study will recruit consecutive eligible dyads in a prospective manner. Statistical analyses will follow a pre-specified plan and will include multivariable regression models to adjust for potential confounding factors. Sensitivity and subgroup analyses, including analyses by delivery mode and other clinically relevant strata, will be performed when feasible.\n\nThis study is designed to provide prospectively collected, biochemically verified evidence on how prenatal tobacco exposure, classified by cord blood cotinine, relates to immediate neonatal metabolic, hematologic, and physiologic outcomes using measurements that are feasible within routine clinical care.",[223,224,25,225],"Tobacco Smoke Pollution","Maternal Exposure During Pregnancy","Carbon Monoxide Poisoning",[227,228],"Prenatal Tobacco Exposure","Maternal Smoking","2026-04-23",{"date":231,"type":39},"2026-04-29",{"date":203,"type":21},{"date":234,"type":21},"2026-10-01",{"name":236,"class":97},"Haseki Training and Research Hospital",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":257,"locationsCount":46},"100062628","generic-database-of-very-low-birth-weight-infants-100062628","NCT00063063","Generic Database of Very Low Birth Weight Infants","Generic Database: A Survey of Morbidity and Mortality in Very Low Birth Weight Infants","GDB","Inclusion Criteria:\n\n* Infants inborn at NICHD NRN centers that are:\n* 401-1000 grams birth weight, and\u002For\n* 20 0\u002F7 to 28 6\u002F7 weeks (\\\u003C29 weeks) gestational age\n* Infants enrolled in one or more additional NICHD NRN interventional trials or time-limited observational studies. For infants that do not meet the inclusion criteria above, inclusion and exclusion criteria for the Generic Database are determined by the criteria for the additional trial(s). In these cases, infants that are larger than 1,000 grams and\u002For older than 29 weeks may be included in the GDB.\n\nExclusion Criteria:\n\n* Infants \\>1,000 grams birth weight and\u002For \\>29 weeks gestational age\n\nNote: These inclusion criteria were changed as of 1\u002F1\u002F2008. Prior to this date, all infants with birth weights between 401 and 1500 grams who are admitted to NRN NICUs within 14 days of birth were included in the database.","14 Days",{"count":247,"type":21},80000,"The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is \"generic\"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.",[25,26,27,28],[30,31,32],"2026-03-12",{"date":253,"type":39},"2026-03-16",{"date":255,"type":39},"1987-04-01",{"date":43,"type":21},{"name":30,"class":45},{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":107,"sex":16,"minAge":265,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":57,"phases":269,"briefSummary":270,"conditions":271,"keywords":272,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":98},"100616192","effect-of-paternal-touch-on-sucking-performance-comfort-and-glucose-levels-in-newborns-at-risk-for-hypoglycemia-100616192","NCT07302412","Effect of Paternal Touch on Sucking Performance, Comfort, and Glucose Levels in Newborns at Risk for Hypoglycemia","The Effect of Paternal Touch on Sucking Performance, Comfort, and Glucose Levels in Newborns at Risk for Hypoglycemia During the First Hours of Life","Inclusion Criteria:\n\n* Newborns identified as being at risk for hypoglycemia (see study population).\n* Newborns whose parents\u002Flegal guardians have provided written informed consent.\n* Clinically stable newborns who have no contraindications to breastfeeding during the first 6 hours after birth.\n* Newborns whose fathers are present during the first 6 hours after birth.\n\nExclusion Criteria:\n\n* Newborns who develop hypoglycemia during the study period or who require initiation of hypoglycemia treatment.\n* Newborns with congenital anomalies or a diagnosed genetic syndrome.","1 Hour","6 Hours",{"count":268,"type":21},98,[160],"This randomized controlled trial aims to examine the effects of Gentle Human Touch applied by fathers during the first hours of life on sucking performance, comfort level, and blood glucose values in newborns at risk for hypoglycemia. Eligible newborns will be randomly assigned to intervention and control groups.\n\nAfter the newborn is taken to the baby care room and routine care procedures are completed, comfort level will be assessed by the primary nurse and an independent second observer using the Neonatal Comfort and Behavior Scale (NCBS). In the intervention group, the first Gentle Human Touch application will begin after routine care and the initial comfort assessment are completed. Sucking performance will be assessed during the first breastfeeding session by the primary nurse and an independent observer using the LATCH Breastfeeding Assessment Tool.\n\nIn the intervention group, fathers will administer 15-minute Gentle Human Touch sessions every hour for six hours according to a structured protocol. In the control group, routine care will be provided without any additional touch.\n\nIn both the intervention and control groups, blood glucose levels will be measured at the 2nd hour according to clinical protocols. At the 6th hour, the newborn's comfort level (NCBS), sucking performance (LATCH), and blood glucose level will be reassessed and recorded.\n\nThis study aims to determine whether early paternal touch supports glucose stability, improves sucking performance, and enhances comfort in newborns at risk for hypoglycemia, and to contribute to the development of family-centered, non-invasive care practices in neonatal settings.",[25],[273,274,275,276,277,278,279],"Gentle Human Touch","Paternal Touch","Newborn Feeding Performance","Comfort","Infant,","Blood Glucose","Newborn","2026-03-10",{"date":282,"type":39},"2026-03-11",{"date":284,"type":39},"2026-01-05",{"date":286,"type":21},"2027-12-08",{"name":288,"class":97},"Acibadem University",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":16,"minAge":297,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":57,"phases":300,"briefSummary":301,"conditions":302,"keywords":309,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":320},"100604546","supraglottic-airway-for-resuscitation-trial-100604546","NCT07150923","Supraglottic Airway for Resuscitation Trial","Comparing Two Multicomponent Strategies To Promote Supraglottic Airway Implementation During Neonatal Resuscitation","SUGAR","Population 1: Hospital Staff\n\nPopulation 1a: Clinical providers and administrators who complete study questionnaires\n\nClinical provider 1a inclusion criteria:\n\n* Employed full-time by the hospital, affiliated practice, or affiliated university in a role that involves newborn resuscitation\n* Fluent in English\n\nAdministrator 1a inclusion criteria\n\n* Oversee the care of newborns on a local level (e.g. nurse manager) or a hospital level (e.g. Chief Quality and Safety Officer)\n* Fluent in English\n\nClinical provider and administrator exclusion 1a criteria: No exclusion criteria\n\nPopulation 1b: Clinical providers who participate in qualitative interviews\n\nClinical provider 1b inclusion criteria:\n\n* Employed full-time by the hospital, affiliated practice, or affiliated university in a role that involves newborn resuscitation\n* Fluent in English\n\nClinical provider 1b exclusion criteria: No exclusion criteria\n\nPopulation 2: Patients who receive neonatal resuscitation at birth\n\nInclusion Criteria:\n\n* Inborn (not transferred to the hospital after birth)\n* ≥34 weeks' gestation at birth, based on best obstetrical estimate\n* Received PPV during neonatal resuscitation (as per provider's clinical assessment)\n\nExclusion Criteria:\n\n* Congenital diaphragmatic hernia\n* Airway anomalies","0 Days",{"count":299,"type":21},36503,[160],"This is a hybrid type 3 effectiveness-implementation parallel cluster randomized superiority trial designed to compare two strategies to promote early supraglottic airway (SA) rescue during neonatal resuscitation, with a focus on implementation outcomes.",[303,304,305,25,306,307,308],"Neonatal Resuscitation","Delivery Room Resuscitation","Positive Pressure Ventilation","Supraglottic Airway","Laryngeal Mask Airways","Implementation Research",[303,304,310,306,307,308,25],"Positive pressure ventilation","2026-02-26",{"date":313,"type":39},"2026-02-27",{"date":315,"type":39},"2026-01-01",{"date":317,"type":21},"2029-09",{"name":319,"class":97},"Children's Hospital of Philadelphia",30,{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":16,"minAge":297,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":57,"phases":330,"briefSummary":331,"conditions":332,"keywords":346,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":98},"100613028","integrating-systems-and-basic-income-improving-outcomes-for-families-of-young-children-100613028","NCT07261254","Integrating Systems and Basic Income: Improving Outcomes for Families of Young Children","Advancing Health Equity Via Basic Income + Early Childhood Systems Integration: An RCT of the Baby Bonus Program","Inclusion Criteria:\n\nCaregiver Eligibility Criteria\n\n* 18 and Older\n* Family plans to reside in San Mateo County\n* Does not plan to move from the County in the next year\n* Speaks English and\u002For Spanish\n* Cared for in Postpartum Maternity unit\n\nChild Eligibility Criteria\n\n* Baby is being cared for in well newborn nursery\n* Child is enrolled in Medicaid\n* 36 weeks or older\n* To be discharged home in the custody of the caregiver\n\nExclusion Criteria:\n\nCaregiver Exclusion Criteria\n\n* Will not consent to share data via Epic\u002FStudy\n* Caregiver has significant cognitive impairment\n* Caregiver under contact isolation\n\nChild Exclusion Criteria\n\n* Sibling already enrolled in the Baby Bonus Study\n* Child has significant genetic disorder issues at birth\n* Child is a multiple (not a singleton)",{"count":329,"type":21},2400,[160],"Early childhood is a critical period, laying the foundation for future growth and deveopment. This foundational period has an outsized effect, impacting health, well-being and achievement across one's lifespan. The U.S. lacks a cohesive early childhood system to support families with young children ages 0-5. The goal of this randomized controlled trial(RCT) is to test if community-based support via community health workers(CHWs) improves social and health services utilization, and child development. Furthermore, the trial will examine if income support enhances the impact of a CHW integrated system. Participants are English and Spanish speaking families with healthy newborns. This RCT was designed based on family priorities, community capacity and needs in a collective impact model. This trial is anchored at a university based children's hospital and involves many partners: families, county health, county leadership, a leading early childhood non-profit organization, the county's Medicaid managed care organization.",[333,25,334,335,336,337,338,339,340,341,342,343,344,345],"Income","Mothers","Poverty","United States","Healthcare Disparities","Child Care","Child Health","Community Health Workers","Hispanic or Latino","Medicaid","Child Development","Social Services Utilization","Health Services Utilization",[347,340,342,348,349,350,351,352,353,197,354],"Guaranteed Basic Income","Medi-Cal","Community Partners","Coordinated Care","Coordinated Services","randomized trial","surveys","newborn nursery","2026-02-10",{"date":357,"type":39},"2026-02-12",{"date":359,"type":39},"2025-04-07",{"date":361,"type":21},"2030-03",{"name":363,"class":97},"Stanford University",{"id":365,"slug":366,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":107,"sex":16,"minAge":4,"maxAge":371,"enrollmentInfo":372,"targetDuration":4,"studyType":57,"phases":374,"briefSummary":375,"conditions":376,"keywords":391,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":147},"100609268","infant-microbiota-restoration-with-maternal-microbes-100609268","NCT07212361","Infant Microbiota Restoration With Maternal Microbes","MaMi","Inclusion Criteria:\n\n* Healthy mother and healthy pregnancy\n* Singleton pregnancy,\n* Mothers who speak Finnish or Swedish\n* Mothers who are planning to breastfeed or give breastmilk by bottle to the infant\n* Infants who are expected to be healthy and who will not require BCG vaccination.\n\nExclusion Criteria:\n\n* Participants who lives further than a 2-hour drive from Meilahti, Helsinki, Finland\n* Mothers who are not planning to breastfeed or feed breastmilk by bottle to the infant\n* Mothers who are diagnosed with gestational diabetes, pre-eclampsia or who have been receiving antibiotics during the pregnancy or delivery\n* Premature infants born before the pregnancy week 37\n* Infants, who are born by urgent cesarean section or emergency cesarean section\n* Infants, who receive antibiotics during the first week of life\n* Infants, who are diagnosed with a disease, congenital anomaly or who receive less than 9 Apgar points at 5 minutes.\n* Infants, who receive BCG-vaccine","50 Years",{"count":373,"type":21},100,[160],"The goal of this clinical trial is to test the ability of different bacterial products in restoring natural gut microbiota in C-section born infants. The main question it aims to answer is:\n\nDo maternally derived strains of bacteria perform better than commercially available probiotic strains in restoring the gut microbiota of C-section born infants? Researchers will compare the gut microbiota of treated infants to that of untreated C-section born infants and untreated vaginally born infants to see if the bacterial treatments cause the microbiota to resemble that of vaginally born infants.\n\nParticipants will be given a bacterial product orally once daily for either one or four weeks and be asked to collect faecal, urine and saliva samples.",[25,377,378,379,380,381,382,383,384,385,386,387,388,389,390],"Gut -Microbiota","Gut Dysbiosis","Cesarean Delivery Affecting Newborn","Cesarean Section","Vaginal Delivery","Gastrointestinal Microbiota","Microbiota, Cesarean Section, Probiotics, Dysbiosis","Feces","Delivery, Obstetric","Microbiota","Microbiology","Humans","Pregnancy","Neonate",[392,120,393,121,394,395],"Infant","cesarean section","restore","gut microbiota","2025-09-30",{"date":398,"type":39},"2025-10-08",{"date":400,"type":39},"2025-07-17",{"date":402,"type":21},"2035-12-31",{"name":404,"class":97},"University of Helsinki",{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":415,"conditions":416,"keywords":419,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":98},"100577354","a-study-of-females-with-cf-throughout-pregnancy-and-post-partum-and-follow-up-of-their-offspring-100577354","NCT06797206","A Study of Females With CF Throughout Pregnancy and Post-partum, and Follow up of Their Offspring","An Observational Study to Evaluate the Impact of Pregnancy and Parenthood in Females With Cystic Fibrosis and Their Offspring in the CFTR Modulator Era.","MATRIARCH_CF","Inclusion Criteria:\n\n'Mama' sub-study:\n\n* Written informed consent obtained from participant.\n* Under the care of Royal Brompton Hospital CF Reproductive and Maternal Health Service\n* Age 16 years or above at time of recruitment\n* Confirmed diagnosis of CF\n* Planning a pregnancy or pregnant at time of recruitment.\n* Ability to adhere to the required visits and investigations.\n\n'Mini' sub-study:\n\n* Written informed consent obtained from participant's legal guardian.\n* Infants who have one biological parent with a confirmed diagnosis of CF under care of Royal Brompton Hospital Adult CF Service\n* Less than 12 months of age at first visit.\n* Ability to adhere to the required visits and investigations.\n\n'Midi' sub-study:\n\n* Written informed consent obtained from participant's legal guardian.\n* Children who have one biological parent with a confirmed diagnosis of CF who is under the care of Royal Brompton Hospital Adult CF Service.\n* Age three to six years at time of visit\n* Ability to adhere to the required visits and investigations.\n\nExclusion Criteria:\n\n'Mama' sub-study:\n\n* Any significant health condition which would cause inability to comply with protocol based on investigator discretion.\n* History of lung transplantation\n\n'Mini' sub-study:\n\n* Legal guardians' inability to provide consent to participate in the study.\n* Mother of infant has significant comorbidities unrelated to CF which could affect infant outcomes based on investigator discretion.\n\n'Midi' sub-study:\n\n* Legal guardians' inability to provide consent to participate in the study.\n* A significant health condition which is known to affect lung function or imaging based on investigator discretion",{"count":414,"type":21},60,"In this study, investigators aim to study in detail the physical (including nutritional and pulmonary) and mental health of females with cystic fibrosis (CF) planning a pregnancy, during pregnancy, and in the early parenthood period.\n\nAdditionally the health of offspring in infancy and early life will be studied to understand if further screening investigations or clinical care models should be part of clinical guidelines",[417,389,25,418],"Cystic Fibrosis (CF)","Exposure During Pregnancy",[420,389,421],"Pregnancy\u002Fobstetric health in women with cystic fibrosis","CFTR modulators","2025-09-26",{"date":424,"type":39},"2025-10-01",{"date":426,"type":39},"2025-06-12",{"date":428,"type":21},"2028-05",{"name":430,"class":97},"Royal Brompton & Harefield NHS Foundation Trust",{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":11,"sex":16,"minAge":265,"maxAge":438,"enrollmentInfo":439,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":441,"conditions":442,"keywords":451,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":147},"100601977","heterogeneity-index-in-neonatologist-performed-lung-ultrasound-in-neonates-receiving-respiratory-support---a-pilot-study-100601977","NCT07117513","Heterogeneity Index in Neonatologist-performed Lung Ultrasound in Neonates Receiving Respiratory Support - a Pilot Study","NPLUS HI","Inclusion Criteria:\n\n* Preterm neonates born between 28+0 and 36+6 weeks of gestation and term-born neonates (\\> 37+0 weeks of gestation) admitted to the NICU\n* Presence of respiratory distress requiring respiratory support (invasive and non-invasive) at the timepoint of NPLUS 1.\n* Written informed consent obtained from the parents prior to the measurement.\n\nExclusion Criteria:\n\n* cardiopulmonary malformations\n* pleural effusion\n* pneumothorax","7 Days",{"count":440,"type":21},40,"Lung ultrasound is an increasingly valuable diagnostic tool in neonatal intensive care due to its safety and accessability.\n\nThis pilot study investigates whether a quantitative approach - the heterogeneity index, previously only used in fetal lung assessment - can enhance the diagnostic accuracy of neonatologist-performed lung ultrasound (NPLUS). The index will be calculated from raw ultrasound images of preterm and term neonates and compared with conventional lung ultrasound scores to evaluate its clinical relevance.",[443,25,28,444,165,445,446,447,448,449,450],"Intensive Care Units, Neonatal","Point-of-Care Systems","Lung Ultrasound","Lung Ultrasound Score","Image Interpretation, Computer Assisted","Reproducibility of Results","Respiratory Distress Neonatal","Respiratory Support",[452,445,446,453,454,455,456,457,458,459,120],"Neonatologist-Performed Lung Ultrasound","Quantitative Lung Ultrasound","Neonatal Intensive Care Unit","Observer Variability in Imaging","Ultrasound Artifact Interpretation","Respiratory Distress Syndrome in Neonates","respiratory support","preterm neonate","2025-08-05",{"date":462,"type":39},"2025-08-12",{"date":464,"type":21},"2025-08-15",{"date":466,"type":21},"2026-08-01",{"name":468,"class":97},"Medical University of Graz",{"id":470,"slug":471,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":11,"sex":477,"minAge":478,"maxAge":371,"enrollmentInfo":479,"targetDuration":4,"studyType":57,"phases":481,"briefSummary":482,"conditions":483,"keywords":501,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":513,"leadSponsor":515,"locationsCount":98},"100598934","comparing-integrative-midwife-led-vs-fragmented-inpatient-postpartum-care-impact-on-satisfaction-and-transition-to-motherhood-100598934","NCT07077941","Comparing Integrative Midwife-led vs. Fragmented Inpatient Postpartum Care: Impact on Satisfaction and Transition to Motherhood","Supporting Mothers With Integrative Care by Midwives for Lifelong Empowerment (SMILE): A Randomized Controlled Trial Comparing Midwife-led Integrative and Fragmented Standard Inpatient Postpartum Care Models on Maternal Satisfaction and Transition to Motherhood","SMILE","Inclusion Criteria:\n\n* Women aged 18 to 50 years at the time of delivery\n* Classified as \"low-risk\" by the obstetric team in the delivery room\n* Gestational age at birth between 36+0 and 42+0 weeks\n* Singleton birth (only one child born)\n* Intent to breastfeed\n* Consent to participate in the study\n\nExclusion Criteria:\n\n* Women younger than 18 or older than 50 at the time of delivery\n* Classified as \"high-risk\" by the obstetric team\n* Multiple birth (e.g., twins, triplets)\n* No intention or ability to breastfeed the newborn","FEMALE","18 Years",{"count":480,"type":21},784,[160],"The goal of this clinical trial is to compare two different forms of postnatal care to find out which is most beneficial for mothers and their children after birth and with which they are most satisfied. One is a nurse-led, seperate model of care and the other is a midwife-led, integrative model of care. Participants are healthy women between the ages of 18 and 50. They gave birth between 36+0 and 42+0 weeks of pregnancy and had a child. The type of birth is not an inclusion or exclusion criteria. Our hypotheses are: i) that maternal satisfaction with care in a midwife-led, integrative care model is higher than in separate maternal and infant care; ii) that a positive postpartum experience leads to earlier and increased maternity competence; iii) that a higher breastfeeding rate at the time of the survey in the fourth month can be achieved through integrative care. Participants will be randomly assigned, after birth of their child, to either the group cared for by a nurse or the group cared for by a midwife.",[484,25,485,486,487,488,489,490,491,492,493,494,495,496,497,498,499,500],"Maternal Health Services","Postnatal Care","Breast Feeding","Maternal-Child Relations","Postpartum Depression (PPD)","Mental Health","Lactation","Breast Feeding, Exclusive","Patient Satisfaction and Experience With Integrative Therapies","Neonatal Jaundice","Maternal Behavior","Body Weight Decreased","Breast Feeding of Healthy Full Term Infants","Lactation Mastitis","Lactation Disorder - Postpartum Condition or Complication","Lactation Disorder With Baby Delivered","Lactation; Insufficient, Partial",[502,503,504,505,506,507,508],"Postnatal care","inpatient","maternity competence","satisfaction","integrative care","breastfeeding","maternal behavior","2025-07-12",{"date":511,"type":39},"2025-07-22",{"date":424,"type":21},{"date":514,"type":21},"2026-12-31",{"name":516,"class":97},"Medical University of Vienna",{"id":518,"slug":519,"hasResults":11,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":11,"sex":16,"minAge":297,"maxAge":156,"enrollmentInfo":525,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":527,"conditions":528,"keywords":530,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":98},"100577838","delivery-room-intervention-and-evaluation-network-100577838","NCT06803498","Delivery Room Intervention and Evaluation Network","Delivery Room Intervention and Evaluation (DRIVE) Network","DRIVE Network","Inclusion Criteria:\n\nInborn infant in receipt of a significant resuscitation intervention (CPAP, PPV, intubation, or CPR) at birth\n\nExclusion Criteria:\n\nNot live born",{"count":526,"type":21},3000000,"The American Academy of Pediatrics (AAP) convened the multi-center Delivery Room Intervention and Evaluation (DRIVE) Network to establish essential infrastructure to collect, coordinate, and analyze core demographic, resuscitative, and outcome data for an inclusive and diverse population of infants who receive delivery room resuscitation at participating centers. The DRIVE Network consists of delivery hospitals across the United States, covering a range of geographic, urban\u002Frural, racial\u002Fethnic diversity across the country. Together, DRIVE seeks to compare practice-level delivery system characteristics, identify best practices, evaluate outcomes from various interventions, and promote professional development through dissemination via the wide reach of the Neonatal Resuscitation Program.",[529,25],"Resuscitation",[531,532,533,534],"Continuous Positive Airway Pressure","Intermittent Positive Pressure Ventilation","Intubation, Intratracheal","Cardiopulmonary Resuscitation","2025-01-27",{"date":537,"type":39},"2025-01-31",{"date":539,"type":39},"2022-01-01",{"date":541,"type":21},"2042-01-01",{"name":543,"class":97},"American Academy of Pediatrics",{"id":545,"slug":546,"hasResults":11,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":107,"sex":477,"minAge":478,"maxAge":552,"enrollmentInfo":553,"targetDuration":4,"studyType":57,"phases":555,"briefSummary":556,"conditions":557,"keywords":559,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":98},"100573785","the-half-swaddling-application-on-infant-sleep-routine-maternal-sleep-quality-depression-100573785","NCT06750796","The Half Swaddling Application on Infant Sleep Routine, Maternal Sleep Quality, Depression","The Effect of Half Swaddling Application on Infant Sleep Routine, Maternal Sleep Quality and Postpartum Depression in Term Infants","Half swaddling","Inclusion Criteria:\n\n* 18-45 years old,\n* Term birth (single birth over 37 weeks),\n* After an uncomplicated pregnancy process, the delivery was completed by normal vaginal or cesarean delivery method,\n* Not using cigarettes, alcohol and stimulants,\n* BMI\\\u003C30,\n* Not working on night shift,\n* Stable vital signs,\n* Those who have not received infertility treatment,\n* Do not have a chronic disease (such as hypertension, diabetes mellitus),\n* Not experiencing serious depression, anxiety and stress,\n* Not having any organic or non-organic disease that can cause cognitive impairment (such as Delirium, Dementia, Intellectual Retardation, etc.),\n* No serious maternal complications,\n* Mothers who volunteered to participate in the study will be included in the study.\n\nFor baby;\n\n* Birth weight over 2500 g,\n* Stable vital signs,\n* APGAR score above 7,\n* No serious neonatal complications,\n* Midwives without congenital malformations will be included in the study.\n\nExclusion Criteria:\n\n* under 18 years old,\n* Preterm birth (under 37 weeks and\u002For multiple births),\n* Incomplete delivery by normal vaginal or cesarean delivery method after a complicated pregnancy process,\n* Using cigarettes, alcohol and stimulants,\n* BMI\\>30,\n* Working night shift,\n* No stable vital signs,\n* Having received infertility treatment,\n* Having a chronic disease (such as hypertension, diabetes mellitus),\n* Experiencing severe depression, anxiety and stress,\n* Having any organic or non-organic disease that can cause cognitive impairment (such as Delirium, Dementia, Intellectual Retardation, etc.),\n* Serious maternal complication,\n* Mothers who do not volunteer to participate in the study will not be included in the study.\n\nFor baby;\n\n* Birth weight of 2500 g and below,\n* No stable vital signs,\n* APGAR score below 7,\n* Serious neonatal complication,\n* Babies with congenital malformations will not be included in the study.","45 Years",{"count":554,"type":21},128,[160],"In this prospective controlled study, it was aimed to examine the effects of half swaddling in term infants on infant sleep routine, maternal sleep quality and postpartum depression.",[25,558],"Maternal Outcome",[392,560,561,562],"half swaddling","maternal sleep quality","postpartum depression","2024-12-26",{"date":565,"type":39},"2024-12-27",{"date":567,"type":39},"2023-05-18",{"date":569,"type":21},"2025-12-15",{"name":571,"class":97},"Tanta University"]